Boston Scientific (BSX) AI Stock Analysis

• Market Cap: $154.04B
• Dividend Yield: N/A
• Average Volume (3M): 9.35M
• Price to Earnings (P/E): 76.3
• Beta (1Y): 0.86
• Revenue Growth: 19.35%
• EPS Growth: 14.31%
• Country: US
• Employees: 53,000
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Devices
• EPS (TTM): 0.75
• Shares Outstanding: 1,479,446,300
• 10 Day Avg. Volume: 7,626,410
• 30 Day Avg. Volume: 9,352,726
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.05
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 14.08
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $119.53
• Price Target Upside: 16.21% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 18

Boston Scientific exhibits a strong financial performance with robust revenue growth and operational efficiency. The earnings call provided positive guidance, reinforcing growth prospects despite challenges like tariffs and foreign exchange impacts. However, the high valuation metrics suggest potential overvaluation, and technical indicators indicate a possible overbought condition, which could lead to future stock price corrections. Overall, the company maintains a favorable position in the medical devices sector.

Positive Factors

Earnings

BSX's revenue and EPS came in ahead of both analyst and consensus expectations, showcasing strong operational performance.

Growth Potential

Management raised its FY25 guidance ahead of consensus estimates, highlighting strong performance and growth potential.

Reimbursement

Recent positive updates on reimbursement for AGENT include the approval for new technology add-on payment and additional reimbursement in the outpatient setting.

Negative Factors

Competition

BSX sees some headwind from low-cost competition in urology and endoscopy, particularly outside the US.

Tariff Impact

BSX expects a tariff impact of ~$200M in 2H25 but expects this to be offset by improved revenue growth, reduced discretionary spending, and currency.

Boston Scientific Business Overview & Revenue Model

Company Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

How the Company Makes Money

Boston Scientific generates revenue primarily through the sale of its medical devices and technology solutions across its various sectors. The company's key revenue streams stem from its Cardiovascular, Rhythm and Neuro, and MedSurg segments. Within these segments, Boston Scientific offers products such as pacemakers, implantable cardioverter-defibrillators, heart valves, stents, endoscopes, and surgical instruments. Additionally, the company engages in strategic partnerships and collaborations with healthcare providers, research institutions, and other industry players to enhance its product offerings and expand its market reach. Factors such as innovation in medical technology, an aging population, and rising global demand for healthcare solutions significantly contribute to its earnings.

Boston Scientific Financial Statement Overview

Summary

Boston Scientific presents a strong financial profile with consistent revenue growth, solid profitability, and efficient cash flow management. The company's balanced approach between leveraging debt and maximizing equity returns supports its strategic growth initiatives in the medical devices sector. However, attention to further debt reduction could enhance financial resilience.

Income Statement

Boston Scientific has demonstrated robust growth in its revenue, with a notable TTM (Trailing-Twelve-Months) increase of 4.81% compared to the previous year. The company maintains strong gross and net profit margins at 67.15% and 11.57% respectively, indicating efficient cost management and profitability. The EBIT and EBITDA margins are solid at 17.52% and 21.65%, reflecting operational efficiency. Overall, the company shows a positive growth trajectory in the medical devices industry.

Balance Sheet

The balance sheet reflects a healthy financial position with a Debt-to-Equity ratio of 0.51, showing manageable leverage. The Return on Equity (ROE) stands at a strong 9.15%, indicating effective utilization of shareholders' equity. The Equity Ratio is 55.33%, suggesting a stable asset base supported by equity. Overall, the company maintains a strong balance between debt and equity, although there is room for improvement in reducing debt levels.

Cash Flow

Boston Scientific exhibits strong cash flow management with a Free Cash Flow growth rate of 8.62%, indicating improved cash generation. The Operating Cash Flow to Net Income ratio is 1.88, demonstrating the company's ability to convert income into cash efficiently. The Free Cash Flow to Net Income ratio is 1.41, reflecting good cash flow productivity. Overall, the company shows robust cash flow health, supporting its financial stability and operational needs.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
16.75B	14.24B	12.68B	11.89B	9.91B
	Gross Profit
11.49B	9.89B	8.68B	8.13B	6.40B
	EBIT
2.60B	2.34B	1.65B	2.04B	1.04B
	EBITDA
3.94B	3.45B	2.74B	2.52B	1.51B
	Net Income Common Stockholders
1.85B	1.59B	698.00M	1.04B	-140.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
414.00M	865.00M	928.00M	1.93B	1.73B
	Total Assets
39.40B	35.14B	32.47B	32.23B	30.78B
	Total Debt
11.15B	9.49B	9.28B	9.45B	9.54B
	Net Debt
10.73B	8.63B	8.35B	7.53B	7.80B
	Total Liabilities
17.39B	15.61B	14.90B	15.61B	15.45B
	Stockholders Equity
21.77B	19.28B	17.57B	16.62B	15.33B
Cash Flow		Free Cash Flow
2.65B	1.70B	914.00M	1.32B	1.13B
	Operating Cash Flow
3.44B	2.50B	1.53B	1.87B	1.51B
	Investing Cash Flow
-5.69B	-2.57B	-2.01B	-1.60B	-411.00M
	Financing Cash Flow
1.81B	5.00M	-548.00M	-95.00M	293.00M

Boston Scientific Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 102.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSX, the sentiment is Positive. The current price of 102.86 is above the 20-day moving average (MA) of 99.92, above the 50-day MA of 99.30, and above the 200-day MA of 91.23, indicating a bullish trend. The MACD of 1.72 indicates Negative momentum. The RSI at 57.11 is Neutral, neither overbought nor oversold. The STOCH value of 53.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BSX.

Boston Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABT	79 Outperform	$231.50B	17.20	30.66%	1.71%	5.00%	139.98%
BSX	78 Outperform	$154.04B	76.29	9.65%	―	19.35%	14.31%
SYK	78 Outperform	$144.36B	51.04	14.26%	0.86%	10.76%	-15.22%
DXCM	76 Outperform	$32.00B	60.26	23.72%	―	9.11%	-17.87%
MDT	75 Outperform	$105.58B	25.36	8.42%	3.35%	2.72%	4.48%
EW	71 Outperform	$43.88B	30.26	16.73%	―	-9.84%	-35.77%
Sector *	52 Neutral	$5.15B	3.56	-42.19%	2.83%	14.48%	-0.49%

Boston Scientific Corporate Events

Boston Scientific Stockholders Approve Key Governance Proposals

On May 1, 2025, Boston Scientific held its Annual Meeting of Stockholders virtually, where all 10 director nominees were elected for a one-year term. Additionally, stockholders approved the compensation for the company’s Named Executive Officers, ratified the appointment of Ernst & Young LLP as the independent public accounting firm for 2025, and supported a proposal for a simple majority vote, indicating strong shareholder engagement and support for the company’s governance and strategic direction.

Spark’s Take on BSX Stock

According to Spark, TipRanks’ AI Analyst, BSX is a Outperform.

Boston Scientific has a robust financial performance and positive earnings outlook, with strong growth in key segments. However, valuation concerns and potential market corrections due to technical indicators may pose risks. Overall, the company holds a favorable position in the medical devices sector, but careful monitoring of external challenges such as tariffs is advised.

To see Spark’s full report on BSX stock, click here.

Boston Scientific Announces CFO Retirement and Successor

On April 23, 2025, Boston Scientific announced the retirement of Dan Brennan, its Chief Financial Officer, after nearly 30 years with the company. Brennan will be succeeded by Jon Monson, currently the Senior Vice President of Investor Relations, effective June 30, 2025. Monson, with over 25 years at Boston Scientific, brings extensive financial expertise and will oversee several key company functions. This leadership transition is expected to ensure continuity and further strengthen the company’s financial strategies and operations.

Spark’s Take on BSX Stock

According to Spark, TipRanks’ AI Analyst, BSX is a Outperform.

Boston Scientific shows robust financial performance with strong revenue growth and effective cash management. Despite this, the stock’s technical indicators suggest a bearish trend, and its high P/E ratio indicates potential overvaluation. The positive sentiment from the earnings call and promising guidance for 2025 provide a positive outlook, but challenges such as pricing pressures in China and currency impacts remain concerns.

To see Spark’s full report on BSX stock, click here.